Sirolimus and Hepatitis - a phase IV clinical study of FDA data

Summary:

Hepatitis is reported as a side effect among people who take Sirolimus (sirolimus), especially for people who are male, 2-9 old, have been taking the drug for 1 - 6 months also take Mycophenolate Mofetil, and have Hiv infection.

The phase IV clinical study analyzes which people have Hepatitis when taking Sirolimus. It is created by eHealthMe based on reports of 11,812 people who have side effects when taking Sirolimus from the FDA, and is updated regularly.

What is Sirolimus?

Sirolimus has active ingredients of sirolimus. eHealthMe is studying from 11,823 Sirolimus users. Check the latest studies of Sirolimus.

What is Hepatitis?

Hepatitis (inflammation of the liver) is found to be associated with 1,462 drugs and 1,524 conditions by eHealthMe. Check the latest studies of Hepatitis.

On Aug, 10, 2026

11,812 people reported to have side effects when taking Sirolimus.
Among them, 40 people (0.34%) have Hepatitis.

Among these 40 people:

How long have people been on Sirolimus when they have Hepatitis? *

What is the gender of people who have Hepatitis when taking Sirolimus? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Hepatitis when taking Sirolimus? *

What are other drugs people take besides Sirolimus? *

Mycophenolate Mofetil: 16 people, 40.00%
Prednisolone: 14 people, 35.00%
Zidovudine: 9 people, 22.50%
Didanosine: 9 people, 22.50%
Lamivudine: 9 people, 22.50%
Raltegravir: 9 people, 22.50%
Efavirenz: 7 people, 17.50%
Sulfamethoxazole And Trimethoprim: 5 people, 12.50%
Abacavir: 5 people, 12.50%
Cyclosporine: 4 people, 10.00%

What are other side effects people have besides Hepatitis? *

Rashes (redness): 13 people, 32.50%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 11 people, 27.50%
Fever: 11 people, 27.50%
Hyperlipidaemia (presence of excess lipids in the blood): 10 people, 25.00%
Renal Impairment (severely reduced kidney function): 10 people, 25.00%
High Blood Pressure: 10 people, 25.00%
Myopathy (a muscular disease in which the muscle fibres do not function): 10 people, 25.00%
Hepatomegaly (abnormal enlargement of the liver): 9 people, 22.50%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 9 people, 22.50%
Blood Immunoglobulin E Increased: 9 people, 22.50%

What are the existing conditions these people have? *

Hiv Infection: 4 people, 10.00%
Renovascular Hypertension (a syndrome which consists of high blood pressure caused by the kidneys hormonal response): 3 people, 7.50%
Immunodeficiency Disorders: 3 people, 7.50%
Uterine Leiomyosarcoma (uterus cancer of smooth muscle connective tissue): 2 people, 5.00%
Chronic Granulomatous Disease (immune system cells are unable to kill some types of bacteria and fungi): 2 people, 5.00%
Epstein-Barr Viraemia: 1 person, 2.50%
Adenovirus Infection: 1 person, 2.50%
Angiosarcoma (cancer of endothelial-type cells that line vessel walls): 1 person, 2.50%
Aplastic Anemia: 1 person, 2.50%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Sirolimus and have Hepatitis?

- Check whether Hepatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sirolimus:

Sirolimus (11,823 reports)

Hepatitis treatments and more:

Hepatitis (31,197 reports)

Browse all side effects of Sirolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis:

Hepatitis (1,462 drugs)

Browse all the conditions that are associated with Hepatitis:

Hepatitis (1,524 conditions)

Related publications that referenced our studies

Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .
Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on sirolimus (the active ingredients of Sirolimus) and Sirolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.